COVID-19 Vaccine & Therapeutics Tracker

Daiichi Sankyo Co., Ltd.’s mRNA vaccine, DS-5670a , enters phase 1/2 clinical trials in Japan.

The Scientific and Technological Research Council of Turkey’s SARS-CoV-2 VLP Vaccine enters phase 1 clinical trials.

ReCOV , the two-component recombinant protein vaccine developed by the Jiangsu Rec-Biotechnology Co., Ltd, enters phase 1 clinical trials in New Zealand.

AZD1222 (ChAdOx1 nCoV-19) had a 76 percent efficacy rate at preventing symptomatic illness in a new analysis of its major clinical trial in the United States of America which is slightly lower than the level announced earlier this week in a report that was criticized for using outdated information.

ModernaTX, Inc.’s new refrigerator-stable vaccine, mRNA-1283 , starts phase 1 clinical trials in the United States of America.

The University of Hong Kong’s live attenuated influenza vaccine, DelNS1-nCoV-RBD LAIV , enters phase 1 clinical trials.

The AZD1222 (ChAdOx1 nCoV-19) vaccine phase 3 clinical trial met the primary efficacy endpoint in preventing COVID-19 at interim analysis with 79% vaccine efficacy at preventing symptomatic infection, 100% efficacy against severe or critical disease and hospitalization, comparable efficacy result across ethnicity and age, and favourable reactogenicity and overall safety profile according to a press release by AstraZeneca.

AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) vaccine is not associated with an increase in the overall risk of blood clots according to a press release by the European Medicines Agency.

The AZD1222 (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate COVID-19 due to the B.1.351 variant according to a publication in The New England Journal of Medicine of phase 1/2 clinical trial results.

MV-014-212 , the live-attenuated respiratory syncytial virus vector vaccine depveloped by Meissa Vaccines, Inc., starts phase 1 clinical trials in The United States of America.

Novavax’s NVX-CoV2373 demonstrated 100% protection against severe disease, 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain, and 55.4% efficacy in a region where the vast majority of strains are B1.351 escape variants according to a press release of their phase 3 U.K. and phase 2b South Africa clinical trial studies, respectively.

Johnson and Johnson’s single-dose vaccine, Ad26.COV2.S , is approved by The European Medicines Agency for use in the European Union.

COVID-eVax , a DNA plasmid-based vaccine developed by Takis and Rottapharm Biotech, enter phase 1/2 clinical trials in Italy.

Covaxin , a whole-virion inactivated SARS-CoV-2 vaccine developed by Bharat Biotech International, induced high neutralising antibody titres and enhanced cell-mediated immune responses, as well as tolerable safety outcomes according to a publication in The Lancet journal of their phase 1 and 2 clinical trials.

EuCorVac-19 , a protein subunit vaccine developed by EuBiologics Co., enters phase 1/2 clinical trial in the Republic of Korea.

SpFN COVID-19 , a protein subunit vaccine developed by the United States Army Medical Research and Development Command, enters phase 1 clinical trial in the United States of America.

Johnson and Johnson’s single-shot vaccine, Ad26.COV2.S , has been approved by Health Canada.

The European Medicines Agency starts a rolling review of the Sputnik V (Gam-COVID-Vac) COVID-19 vaccine.

SARS-CoV-2 B.1.1.7 was shown to be sensitive to neutralization by serum samples from convalescent individuals and recipients of mRNA-1273 and Novavax vaccines indicating that this variant is unlikely to be a major concern for current vaccines according to a publication in the journal Cell Host & Microbe.

SARS-CoV-2 B.1.1.7 was shown to be sensitive to neutralization by serum samples from convalescent individuals and recipients of mRNA-1273 and NVX-CoV2373 vaccines indicating that this variant is unlikely to be a major concern for current vaccines according to a publication in the journal Cell Host & Microbe.

Covaxin demonstrated 81% interim efficacy in preventing COVID-19 in those without prior infection after the second dose according to a press release by Bharat Biotech.

The protein subunit vaccine EpiVacCorona enters phase 3 clinical trials in Russia.

Vaccination with either a single dose of Comirnaty (BNT162b2) or AZD1222 (ChAdOx1 nCoV-19) was associated with a significant reduction in symptomatic SARS-CoV-2 positive cases in older adults with even greater protection against severe disease and a second dose of the former provides further protection against symptomatic disease according to a publication in the preprint server medRxiv by Public Health England.

Two new COVID-19 vaccines, ChAdV68-S and SAM-LNP-S , developed by the United States National Institute of Allergy and Infectious Diseases enter phase 1 clinical trials.

Johnson and Johnson’s single-shot vaccine, Ad26.COV2.S , has been approved for emergency use by The United States of America Food and Drug Administration.

Health Canada approves the use of AstraZeneca and The University of Oxford’s AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine.

The United States Food and Drug Administration allows Pfizer and BioNTech’s Comirnaty (BNT162b2) to be transported/stored for up to two weeks at standard freezer temperatures.

Moderna, Inc. announces that it has completed manufacturing of its variant-specific vaccine candidate, mRNA-1273 .351, against the SARS-CoV-2 variant B.1.351 and has shipped doses to the National Institutes of Health for a Phase 1 clinical trial.

Providence Therapeutic’s mRNA vaccine, PTX-COVID19-B , enters phase 1 clinical trials in Canada.

A second COVID-19 vaccine developed by SK Bioscience's, NBP2001 , enters phase 1 clinical trials in the Republic of Korea.

A novel inactivated SARS-CoV-2 vaccine, Unnamed Inactive Vaccine - Jiangsu , developed by Beijing Minhai Biotechnology Co., Shenzhen Kangtai Biological Products Co., and the Jiangsu Province Centers for Disease Control and Prevention enters phase 1/2 clinical trials in China.

GlaxoSmithKline’s RNA vaccine, CoV2 SAM (LNP) , enters phase 1 clinical trials in The United States of America.

BBV154 , an intranasally delivered adenovirus-vector vaccine developed by Bharat Biotech International Limited, enters phase 1 clinical trials in India.

AZD1222 (ChAdOx1 nCoV-19) did not show protection against mild-moderate COVID-19 due to the SARS-CoV-2 South African variant (B.1.351), however, efficacy against severe COVID-19 was undetermined according to a publication in the preprint server medRxiv.

COVIGEN , the needle-free DNA COVID-19 vaccine by BioNet enters phase 1 clinical trials in Australia.

SK Bioscience’s COVID-19 vaccine, GBP510 , enters phase 1/2 clinical trial in the Republic of Korea.

Comirnaty (BNT162b2) -elicited antibodies were shown to neutralize the B.1.1.7 SARS-CoV-2 variant in a preprint publication bioRxiv.

CoronaVac had an efficacy rate against diseases caused by COVID-19 of 50.65% for all cases, 83.70% for cases requiring medical treatment, and 100% for hospitalized, severe, and fatal cases according to a press release by the company of their Phase 3 clinical trials result.

Efficacy of AZD1222 (ChAdOx1 nCoV-19) against the B.1.1.7 variant of SARS-CoV-2 is similar to that of other lineages and vaccination reduces the duration of shedding and viral load according to a preprint publication in The Lancet.

Johnson and Johnson’s single-dose vaccine, Ad26.COV2.S , was shown to be 66% and 85% effective overall at preventing moderate to severe COVID-19 and in preventing severe disease, respectively, and demonstrated complete protection against COVID-19 related hospitalization and death 28 days after vaccination according to a press release about their phase 3 clinical trial.

Novavax’s COVID-19 Vaccine, NVX-CoV2373 , Demonstrated 89.3% Efficacy in their phase 3 clinical trial according to a company press release.

Pfizer and BioNTech’s Comirnaty (BNT162b2) vaccine generates antibodies that neutralize the new South African SARS-CoV-2 variant B.1.351 according to a publication in the preprint server bioRxiv.

Moderna’s vaccine, mRNA-1273 , induces neutralizing antibodies against global SARS-CoV-2 variants from the United Kingdom (B.1.1.7) and South Africa (B.1.351), according to a publication in the preprint server bioRxiv.

Pfizer and BioNTech’s Comirnaty (BNT162b2) vaccine generates antibodies that neutralize the new SARS-CoV-2 variant B.1.1.7 according to a publication in the preprint server bioRxiv.

Sinovac Biotech’s CoronaVac vaccine was 50.4 percent effective at preventing symptomatic infections according to further analysis of their phase 3 clinical trial in Brazil, significantly less than earlier reported (78%).

Johnson and Johnson’s Ad26.COV2.S was shown to be safe and elicit both an antibody and cell-mediated immune response according to an interim analysis of their phase 1/2 clinical trial published in The New England Journal of Medicine.

The University of Saskatchewan’s COVID19 vaccine, COVAC-2 , enters phase 1/2 clinical trials in Canada.

Medigen Vaccine Biologics Corp.’s COVID19 vaccine, MVC-COV1901 , enters phase 2 clinical trials in Taiwan and Vietnam.

The Republic of India approves the use of AstraZeneca and The University of Oxford’s SARS-CoV-2 vaccine, AZD1222 (ChAdOx1 nCoV-19) .

The Republic of India approves the use of Bharat Biotech’s SARS-CoV-2 vaccine, Covaxin .

The Republic of Turkey’s inactive vaccine, ERUCOV-VAC , enters phase 1 clinical trials.

The Republic of Khazakstan’s QazCovid-in COVID19 vaccine enters phase 3 with an expected 3000 participants.

AZD1222 (ChAdOx1 nCoV-19) , the coronavirus vaccine developed jointly by Oxford University and AstraZeneca, is approved for use in The United Kingdom.

In a press release, Arcturus Therapeutics announced phase 1/2 clinical trial data demonstrating favorable tolerability and immunogenicity in 100% (44/44) of LUNAR-COV19 (ARCT-021) vaccinated subjects.

The Results of Inovio Pharmaceuticals’s DNA vaccine phase 1 clinical trial published in the journal EClinicalMedicine indicates that INO-4800 demonstrated excellent safety and tolerability and was immunogenic in 100% (38/38) of the vaccinated subjects.

A new spike protein vaccine, Nanocovax , enters phase 1/2 in Vietnam.

COVAXX’s protein antigen vaccine, UB-612 , enters phase 2/3 clinical trials.

AKS-452 , a new protein vaccine against SARS-CoV-2, developed by Akston Biosciences Corporation enters phase 1/2 clinical trials in the Netherlands.

Health Canada approves Moderna’s COVID-19 vaccine, mRNA-1273 .

AltImmune’s replication-deficient adenovirus type 5 based vaccine, AdCOVID , enters phase 1 clinical trials in The United States of America.

The Results of Bharat Biotech’s inactive SARS-CoV-2 vaccine phase 2 clinical trial published in the preprint server medRxiv reveals Covaxin had tolerable safety outcomes and enhanced humoral and cell-mediated immune responses.

The Results of Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. protein subunit vaccine phase 1/2 clinical trial published in the preprint server medRxiv reveals ZF2001 was well-tolerated and immunogenic.

Takeda’s TAK-919 vaccine enters phase 1/2 clinical trials in Japan.

The European Medical Agency recommends Pfizer and BioNTech’s Comirnaty (BNT162b2) COVID-19 vaccine for authorisation in the European Union.

Moderna’s mRNA-1273 was approved by the United States Food and Drug Administration.

Clover Biopharmaceuticals SCB-2019 vaccine enters phase 2/3 clinical trials.

GeneOne Life Science, Inc.’s DNA vaccine, GLS-5310 , enters phase 1/2 clinical trials in South Korea.

Valneva Austria GmbH’s inactive vaccine, VLA2001 , enters phase 1/2 clinical trials in the United Kingdom.

Cellid Co., Ltd.’s adenovirus-based vaccine, AdCLD-CoV19 , enters phase 1/2 clinical trials in South Korea.

Pfizer and BioNTech’s Comirnaty (BNT162b2) is approved for use in Canada.

First doses of Pfizer’s Comirnaty (BNT162b2) administered in the United Kingdom.

AG0302-COVID19 , AnGes, Inc.’s second COVID-19 vaccine enters phase 2/3 clinical trials in Japan.

Sputnik V (Gam-COVID-Vac) starts phase 3 clinical trials in the United Arab Emerates.

CureVac AG’s CVnCoV enters phase 3 clinical trials in Germany.

The United Kingdom becomes the first country in the world to approve the Pfizer and BioNTech vaccine, Comirnaty (BNT162b2) , for emergency use in its population.

ZF2001 , the recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters phase 3 clinical trials in China.

Moderna’s mRNA-1273 vaccine efficacy against COVID-19 was 94.1% overall and 100% against severe COVID-19 according to a press release detailing their primary efficacy analysis of the Phase 3 COVE study.

Inovio Pharmaceuticals INO-4800 enters phase 2/3 clinical trials in the United States of America.

The Russian Sputnik V (Gam-COVID-Vac) enters phase 3 clinical trials in Venezuela.

Sputnik V (Gam-COVID-Vac) demonstrates 91.4% efficacy after 28 days (n=18,794) and 95% efficacy 21 days after the second dose according to the second interim analysis of clinical trials data in a press release from the Gamaleya Center team.

Interim analysis of clinical trials of AZD1222 (ChAdOx1 nCoV-19) demonstrates 90% when given as a half dose, followed by a full dose (n=8,895), and 62% efficacy when given as two full doses (n=11,636) for an average efficacy of 70% according to a press release by AstraZeneca.

The Russian Sputnik V (Gam-COVID-Vac) enters phase 2/3 clinical trials in the Republic of India.

The Unnamed Recombinant Vaccine - Jiangsu from Jiangsu Province Centers for Disease Control and Prevention and West China Hospital enter phase 2 clinical trials in China.

Covaxin , Bharat Biotech International Limited’s whole, inactive SARS-CoV-2 virus particle-based vaccine, enters phase 3 in the Republic of India, with an expected enrollment of 25,800 participants.

The City of Hope Medical Center and National Cancer Institue’s synthetic modified vaccinia Ankara-based vaccine, COH04S1 , enter phase 1 clinical trials in the United States of America.

Medicago’s virus-like particle vaccine, CoVLP , enters phase 2/3 clinical trials with expected recruitment of over 30,000 participants.

Pfizer and BioNTech concluded Phase 3 study for their RNA-based vaccine, Comirnaty (BNT162b2) , with 95% efficacy against COVID-19 and good tolerance across all tested demographics.

Moderna’s mRNA-1273 COVID-19 vaccine is 94.5% effective according to first interim analysis of its phase 3 study.

CORVax , a new DNA plasmid vaccine enters phase 1 clinical trials in The United States of America.

Positive phase 3 study interim results were announced for Pfizers and BioNTech’s RNA-based vaccine, Comirnaty (BNT162b2) , with >90% efficacy in preventing COVID-19 across study participants.

A new live-attenuated vaccine against COVID-19, COVI-VAC , starts phase 1 clinical trials in the United Kingdom.

Johnson and Johnson extends Ad26.COV2.S phase 3 clinical trials to multiple sites around the world with an additional 30,000 participants.

NVX-CoV2373 phase 3 clinical trials expand with 30000 additional participants in The United States of America, Mexico and Puerto Rico.

CureVac’s CVnCoV was generally well tolerated across all tested doses and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation in interim data from an ongoing Phase 1 clinical trial.

IIBR-100 , a new replicating COVID-19 vaccine developed by the Israel Institute for Biological Research, starts phase 1/2 clinical trials in Israel.

Johnson & Johnson to Resume Phase 3 clinical trial of its COVID-19 Vaccine Candidate, Ad26.COV2.S , in The United States of America.

The United States of America Food and Drug Administration authorises restart of the COVID-19 AZD1222 (ChAdOx1 nCoV-19) vaccine phase 3 clinical trial.

A new adenoviral-based vaccine, hAd5-S-Fusion+N-ETSD , developed by ImmunityBio, Inc enters phase 1 clinical trials in The United States of America.

Entos Pharmaceutical’s Covigenix VAX-001 enters phase 1 clinical trials in Canada, a DNA plasmid vaccine encoding the viral nucleocapsid antigen.

Comirnaty (BNT162b2) , one of BioNTech and Pfizer’s COVID-19 vaccine candidates, starts phase 1 clinical trials in Japan.

Phase 3 clinical trials for Johnson & Johnson's COVID-19 vaccine candidate, Ad26.COV2.S , have been put on hold due to an ‘unexplained illness’ observed in a study volunteer

Novavax’s protein subunit vaccine, NVX-CoV2373 , starts phase 3 clinical trials in the United Kingdom in combination with the seasonal influenza vaccine.

Sinovac’s inactive vaccine, CoronaVac , enters phase 3 clinical trials in Turkey with an estimated enrollment of 13,000 participants.

Merck Sharp & Dohme Corp.’s second COVID-19 vaccine, V590 , enters Phase 1 clinical trials in the United States of America.

The Results of Moderna and NIAID’s mRNA-1273 vaccine Phase 1 clinical trial in older adults (56+ years of age) published in the New England Journal of Medicine reveals a robust antibody and cellular immune response in vaccinated individuals.

The Universitätsklinikum Hamburg-Eppendorf’s Modified Vaccinia Ankara virus vaccine, MVA-SARS-2-S , enters Phase 1 clinical trials in Germany.

INOVIO’s Phase 2/3 Clinical trial of its COVID-19 vaccine candidate, INO-4800 , has been put on partial clinical hold until questions posed by the U.S. FDA about the candidate and the delivery device (CELLECTRA® 2000) have been satisfactorily addressed. This hold is not due to the occurrence of any adverse events.

Chulalongkorn University’s mRNA vaccine, ChulaCov19 , enters Phase 1 clinical trials in Thailand.

Vaxart’s non-replicating Ad5 vector SARS-CoV-2 vaccine VXA-CoV2-1 enters Phase I clinical trials in the United States of America.

AstraZeneca and the University of Oxford’s Phase 3 clinical trial of AZD1222 (ChAdOx1 nCoV-19) has yet to resume in the United States where the FDA is reported to be requesting further data on the two adverse reactions.

A new multi-peptide based vaccine, CoVac-1 , developed by The University Hospital Tuebingen enters Phase 1 clinical trials in Germany.

Imperial College of London Researchers will begin testing the safety and efficacy of both LNP-nCoVsaRNA and The University of Oxford/AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) when administered by inhalation in a 30 patient initial cohort.

The Phase 3 clinical trial of AZD1222 (ChAdOx1 nCoV-19) resumes after the conclusion of an independent review process and following the recommendations of both the independent safety review committee and the United Kingdom Medicines and Healthcare products Regulatory Agency.

COVAXX and United Biomedical Inc.’s protein subunit vaccine, UB-612 start Phase 1 clinical trials in Taiwan.

Novavax starts Phase 3 clinical trials of its COVID-19 vaccine candidate, NVX-CoV2373 , in the United Kingdom.

Preclinical data of Pfizers and BioNTech’s RNA-based vaccine, Comirnaty (BNT162b2) , published in the preprint server bioRxiv indicate a robust antibody and T cell response in both mice and non-human primates further validating its ongoing human clinical trials.

The University of Oxford and AstraZeneca’s Phase 3 study testing their vaccine candidate, AZD1222 (ChAdOx1 nCoV-19) , was put on hold due to a suspected serious adverse reaction in a United Kingdom trial participant.

Sinovac Biotech states that CoronaVac , its inactive coronavirus vaccine candidate, appeared to be safe for older people, while the elicited immune responses were slightly weaker than for younger adults, according to preliminary results from an early to mid-stage trial.

CanSino Biologics’ Convidicea (Ad5-nCoV) vaccine starts Phase 3 clinica trials in Russia.

The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) starts Phase 3 clinical trials in Russia.

Sanofi and GlaxoSmithKline’s unnamed protein subunit vaccine [ Unnamed Protein Subunit Vaccine - Sanofi/GSK ] enters phase 1/2 clinical trials in the United States.

The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) enters Phase 3 clinical trials in Brazil, with an anticipated enrollment of 5000 participants.

A publication in the New England Journal of Medicine indicates that Novavax’s NVX-CoV2373 appears to be safe, and elicits both a strong antibody and cellular response against SARS-CoV-2.

Novavax’s protein subunit vaccine NVX-CoV2373 enters Phase 2 clinical trials in South Africa.

Sputnik V (Gam-COVID-Vac) enters Phase 3 clinical trials in Russia, with an expected enrollment of 40,000 participants.

QazCovid-in , an inactive viral vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan enters Phase 1/2 clinical trials.

A gorilla adenovirus-based vaccine, GRAd-COV2 , developed by ReiThera Srl and Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani enters Phase 1 clinical trials in Italy.

A second DNA-based vaccine developed by AnGes Inc., AG0302-COVID19 , starts Phase 1/2 clinical trials in Japan.

CanSino Biologics Inc. and Beijing Institute of Biotechnology’s adenovirus-based vaccine candidate, Convidicea (Ad5-nCoV) , enters Phase 3 clinical trials in Pakistan.

Russia’s second vaccine, EpiVacCorona , enters Phase 1 / 2 clinical trials.

The shingles vaccine, Shingrix , enters Phase 1 clinical trials as a preventative agent in elderly individuals for its hypothesized non-specific immunomodulatory effects.

Adimmune’s protein subunit vaccine AdimrSC-2f enters Phase 1 clinical trials in Taiwan.

A preprint publication of Phase 1 clinical trial results in the US supports the selection of Pfizer and BioNTech’s Comirnaty (BNT162b2) vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation.

A Phase 3 trial of the University of Oxford and AstraZeneca’s SARS-CoV-2 vaccine, AZD1222 (ChAdOx1 nCoV-19) , starts in The United States of America in collaboration with Iqvia Pty Ltd with an expected enrollment of 30,000 participants.

CureVac AG’s investigational SARS-CoV-2 mRNA vaccine ( CVnCoV ) enters Phase 2 clinical trials.

An interim report of Phase 1/2 trials of the Unnamed Inactive Vaccine - Wuhan Published in the Journal JAMA indicates that patients had a low rate of adverse reactions and demonstrated high neutralizing antibody titers.

Russia becomes the first country to grant regulatory approval to a coronavirus vaccine, Sputnik V (Gam-COVID-Vac) , prior to its completion of clinical trials.

Sinovac’s inactive vaccine, CoronaVac , was well-tolerated and immunogenic in a preprint publication of Phase 2 clinical trial results that were conducted in a Randomized, Double-blind, and Placebo-controlled fashion in 600 healthy adults.

Janssen Vaccine’s Ad26.COV2.S enters Phase 3 clinical trials, with an estimated enrollment of 60,000 participants worldwide.

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate, NVX-CoV2373 , for local production and commercialization in Japan.

Vaccination with NVX-CoV2373 was generally well-tolerated, induced neutralization antibody titers in 100% of participants, and elicited a robust cellular response in Novavax’s 131 participant Phase 1 clinical trial results.

Merck’s V591 , a SARS-CoV-2 vaccine candidate that uses an attenuated measles virus as a vector, enters Phase 1 clinical trials.

TMV-083 , a vaccine that uses a live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of SARS-CoV-2 enters Phase 1 clinical trials.

A study published in Nature shows the SARS-CoV-2 vaccine Ad26.COV2.S elicits a strong immune response that protects against subsequent infection in a non-human primate model.

In a press release by Inovio, INO-4800 demonstrated the longest-term protection in non-human primates SARS-CoV-2 challenge model (13 weeks post-vaccination). The immunization also elicited antibodies that neutralize newer viral variants.

AZD1222 (ChAdOx1 nCoV-19) elicited a robust immune response in two animal models and prevented pneumonia in a non-human primate model of SARS-CoV-2 infection according to a publication in the journal Nature. However, there was no difference in nasal shedding between vaccinated and control animals.

BioNTech and Pfizer decide upon Comirnaty (BNT162b2) as their candidate vaccines of choice moving forward in Phase 2/3 clinical trials. This study will include up to 30,000 participants at 120 sites worldwide.

MVC-COV1901 , a protein subunit vaccine developed by Medigen Vaccine Biologics Corp. enters Phase 1 clinical trials in Taiwan.

Arcturus Therapeutics’ RNA-based vaccine LUNAR-COV19 (ARCT-021) enters Phase 1/2 clinical trials in Singapore.

A deal securing up to 600 million doses of Comirnaty (BNT162b2) was reached between The U.S. Government, Pfizer, and BioNTech with an assurance that Americans will receive the vaccine for free.

The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) showed an acceptable safety profile as well as elicited both a humoral and cellular immune response in people post-vaccination as demonstrated by a publication in The Lancet. These results support the continued evaluation of this vaccine in Phase III clinical trials.

CanSino’s Convidicea (Ad5-nCoV) vaccine was safe and induced significant immune responses in the majority of recipients after a single immunization according to a publication in The Lancet.

The Unnamed Inactive Vaccine - Wuhan developed by The Wuhan Institute of Biological Products enters Phase 3 clinical trials in The United Arab Emirates.

The Imperial College’s self-amplifying RNA vaccine, LNP-nCoVsaRNA , moves on to Phase 2 clinical trials in The United Kingdom.

KBP-COVID-19 , a vaccine generated by using tobacco plants as bioreactors, enters Phase 1/2 clinical trials.

A new inactive viral vaccines, Covaxin , developed by Bharat Biotech International Limited enters Phase 1/2 clinical trials in the Republic of India.

Interim Phase 1 results for Modern’a mRNA-1273 vaccine were published in the New England Journal of Medicine, indicating that immunization induced anti–SARS-CoV-2 responses in all participants and no trial-limiting safety concerns were identified.

Moderna’s mRNA-1273 enter Phase III clinical trials in the United States of America with a targeted enrollment number of 30,000 participants.

The mRNA vaccine candidate Comirnaty (BNT162b2) , developed by Biontech Pharmaceuticals and Pfizer has received ‘fast-track’ designation from the U.S. FDA.

ZF2001 , the recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters Phase 2 clinical trials in China.

Johnson & Johnson’s non-replicating Adenvirus type-26 based vaccine, Ad26.COV2.S , enters Phase 1/2 clinical trials in The United States of America and Belgium.

A new DNA-based vaccine developed by AnGes Inc., AG0301-COVID19 , starts Phase 1/2 clinical trials in Japan.

Immunization with the repurposed vaccine Bacille Calmette-Guerin* was shown to correlate with reduced mortality according to a study published by The Proceedings of the National Academy of Sciences of the United States of America. Clinical trial results will be required to corroborate these findings.

the mRNA-based vaccine mRNA-1273 , developed by Moderna, closes enrolment for its Phase 2 SARS-CoV-2 study.

Cadila Healthcare Limited’s DNA plasmid vaccine, ZyCoV-D , enters Phase 1/2 clinical trials in The Republic of India.

The inactive vaccine, CoronaVac , developed by Sinovac Biotech starts Phase III clinical trials in Brazil.

The mRNA vaccine candidate, Comirnaty (BNT162b2) , developed by Biontech Pharmaceuticals and Pfizer was shown to be safe, tolerable, and immunogenic in preprint published results of their Phase 1/2 clinical trials.

The DNA plasmid vaccine INO-4800 demonstrates Positive Interim Phase 1 Data according to a press release by Inovio Pharmaceuticals.

The Convidicea (Ad5-nCoV) vaccine, developed by CanSino Biologics Inc., gets approval for military use in China.

CoVLP , a virus-like particle vaccine produced by Medicago Inc. enters Phase I clinical trials.

BBIBP-CorV , the inactive viral vaccine developed by the Beijing Institute of Biological Products and Sinopharm, was found to be safe and able to generate high titers of antibodies among participants in phase I and II clinical trials according to a company press release.

an mRNA vaccine, CVnCoV , developed by CureVac and Coalition for Epidemic Preparedness Innovations enters Phase 1 Clinical trials in Germany.

The DNA plasmid vaccine, INO-4800 , developed by Inovio Pharmaceuticals in collaboration with International Vaccine Institute and Coalition for Epidemic Preparedness Innovations enters Phases 1/2 in the Republic of Korea.

GX-19 , a DNA vaccine expressing SARS-CoV-2 S-protein antigen developed by Genexine, Inc., enters Phase 1/2 clinical trials in the Republic of Korea.

A new recombinant vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., ZF2001 , enters phase 1 clinical trials in China.

News reports indicate that the Unnamed Inactive Vaccine - Wuhan developed by the Wuhan Institute of Biological Products and Sinopharm induced neutralizing antibodies in all vaccinated individuals, and that Phase III clinical trials will start June 23rd in both China and the United Arab Emirates.

AZD1222 (ChAdOx1 nCoV-19) starts Phase 1/2 clinical trials to assess safety, immunogenicity, and efficacy in adults with and without HIV in South Africa. This study is a partnership between the University of Witwatersrand, the University of Oxford, the Medical Research Council of South Africa, and the Bill and Melinda Gates Foundation.

The Unnamed Inactive Vaccine - Yunnan being developed by The Chinese Academy of Medical Sciences enters Phase II of clinical trials testing.

Sputnik V (Gam-COVID-Vac) , a new adenoviral-based vaccine developed by Gamaleya Research Institute, starts phase 1/2 clinical trials in Russia.

A self-amplifying RNA-based vaccine candidate developed by Imperial College London in partnership with Morningside Ventures named CoVac-1 enters Phase 1/2 clinical trials.

AstraZeneca has reached an agreement to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, AZD1222 (ChAdOx1 nCoV-19) , to Germany, France, Italy, and the Netherlands, with deliveries starting by the end of 2020.

Sinovac announces no severe adverse events reported and that neutralizing antibodies developed 14 days after the vaccination in its preliminary results of phase 1/2 clinical trial for the Company’s COVID-19 vaccine candidate, CoronaVac .

June 12th - A new Unnamed Spike Protein Candidate developed by The University of Queensland enters Phase 1 clinical trials in Australia.

A novel protein subunit vaccine created by Vaxine and Medytox, COVAX-19 , enters Phase I clinical trials in the US.

Moderna moves forward with 100 ug dosage for Phase 3 clinical trial of mRNA-1273 and partners with Lonza to scale up manufacturing potential to generate between 500 million and 1 billion vaccine doses per year.

A publication in the journal Cell indicates that administration of Beijing Institute of Biological Products and Sinopharm’s inactive vaccine, BBIBP-CorV , generates high neutralizing antibody titers and is safe, effective, and stable in numerous animals animal models, including non-human primates.

Preprint article in medRxiv indicates that Bacille Calmette-Guerin* vaccination was associated with reduced COVID-19 mortality in level 4:Do Not Travel countries when adjusted for a number of confounding variables.

Novavax secures upto $60M from the U.S. Department of Defense to support the production of their NVX-CoV2373 vaccine. The agreement includes a 2020 delivery of 10 million doses for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by the U.S. FDA.

A report released indicates that the Phase 3 clinical trials for Moderna’s COVID-19 experimental vaccine, mRNA-1273 , will start in July with the enrollment of 30,000 individuals in a randomized, placebo-controlled trial.

mRNA-1273 , the joint vaccine initiative by Moderna, NIAID, and BARDA, enters Phase 2 clinical trials for COVID-19.

The spike protein subunit vaccine by Clover Biopharmaceutical, SCB-2019 , enters Phase 1 clinical trials against COVID-19.

Novavax administrates the NVX-CoV2373 vaccine to the first participants in Phase 1 clinical trial. Phase 2 planned to begin following successful Phase 1 results. On May 11, Novavax secured a $388M grant from CEPI (a Bill & Melinda Gates Foundation-backed vaccine development coalition).

Sinovac Biotech Co. has received $15M in funding to advance the development of its Covid-19 vaccine candidate, CoronaVac .

CanSino Biologics’ Convidicea (Ad5-nCoV) vaccine starts Phase 1/2 clinical trials in Canada against COVID-19 in collaboration with the Canadian Center for Vaccinology.

Phase 1 results for CanSino Biologics’ Convidicea (Ad5-nCoV) vaccine published in The Lancet indicate it was tolerable and immunogenic in humans and warrants further clinical trials testing.

AstraZeneca/The University of Oxford vaccine AZD1222 (ChAdOx1 nCoV-19) starts Phase 2 / 3 clinical trials for COVID-19.

AZD1222 (ChAdOx1 nCoV-19) , developed by the University of Oxford and licensed to AstraZeneca secures $1.2 billion backing from U.S Department of Health for accelerated development.

Publication in Nature Communications demonstrates robust antibody and cellular immunity elicited by Inovio's INO-4800 vaccine in preclinical models.

Inovio Pharmaceuticals press release announces positive interim Phase 1 data for their INO-4800 vaccine.

Inovio Pharmaceutical's INO-4800 vaccine elicits robust immune response in preclinical models as shown in Nature Communications publication.

Moderna press release announces positive interim Phase 1 data for its mRNA Vaccine, mRNA-1273 .

Health Canada approves human testing for CanSino Biologics's Convidicea (Ad5-nCoV) vaccine. Trial will be conducted out of the Canadian Centre for Vaccinology at Dalhousie University.

AV-COVID-19 is a new dendritic cell vaccine in Phases 1/2 clinical trials for COVID-19.

The vaccine for tuberculosis, Bacille Calmette-Guerin* is now in consideration for COVID-19. Undergoing clinical Phases 3/4 trials.